Viralytics on track with IV delivery
Wednesday, 25 June, 2008
Viralytics (ASX: VLA) has completed the first step of phase I clinical trials of its oncolytic virus technology, Cavatrak, for stage IV metastatic melanoma.
The safety trial involved each subject receiving an intravenous injection of Cavatrak. No adverse effects were found in the test subjects, the company said.
Viralytics has also been granted clearance to continue the trials with the next patient group. This cohort will receive two injections of the drug seven days apart.
This trial is being run concurrently with another set of clinical trials of late-stage melanoma patients. The subjects in that trial are being given multiple intra-tumoural injections of Cavatrak in doses up to 100 times the original.
Defective sperm doubles pre-eclampsia risk in IVF patients
A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...
Free meningococcal B vaccines coming to the NT
The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
